Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer
Bevacizumab-Related Serious Adverse Events in mCRC
D Hompes, T Ruers
Yes
20110801
2011 Sept 1
Eur J Surg Oncol
Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer
Eur J Surg Oncol. 2011 Sept 1;37(9):737-746, D Hompes, T Ruers
Abstract
Abstract
Objective and Background: This review describes the extent, frequency and clinical importance of Bevacizumab (BV)-related serious adverse events (SAE) after surgery, during or after chemotherapy with BV in patients with metastatic colorectal cancer (mCRC).Methods: Detailed PubMed search in November 2009.Results: Addition of BV to first- or second-line chemotherapy in patients with mCRC results in a statistically significant benefit in OS, PFS and RR.Addition of BV to chemotherapy causes no clinically...
